Design of the Rituximab in ANCA-Associated Vasculitis (RAVE) Trial

Ulrich Specks, Peter A. Merkel, Gary S. Hoffman, Carol A. Langford, Robert Spiera, Cees G. M. Kallenberg, E. William St. Clair, Linna Ding, Lisa Webber, Masoud Mokhtarani,

The Open Arthritis Journal · 2011 · 20 citations · 35 references

DOIFull text

Open access

Concepts

Abstract

Granulomatosis with polyangiitis (formerly Wegener's) (GPA) and microscopic polyangiitis (MPA) share many clinical and pathological features, including antineutrophil cytoplasmic antibodies (ANCA) directed against either proteinase 3 (PR3) or myeloperoxidase (MPO). These two "ANCA-associated" vasculitides (AAV) are associated with a high mortality in untreated patients, substantial morbidity from standard therapies, and a significant risk of disease relapse.

References

35